Colonic Perforation After Treatment With Nivolumab in Esophageal Cancer: A Case Report
Hye-Jung CHO; Woo-Ram KIM; Joo-Hang KIM; Duk-Hwan KIM; Dae-Jung KIM; Haeyoun KANG.
Annals of Coloproctology
; : S39-S43, 2021.
Artículo
en Inglés
| WPRIM | ID: wpr-889047
With the advent of checkpoint inhibitors, it has opened up opportunities for numerous cancer patients. However, as is the case with every treatment, complications need to be weighed. Gastrointestinal adverse effects, such as diarrhea and colitis are well-known complications for checkpoint inhibitors. In severe cases, colitis-induced colonic perforation may occur with an estimation of 1.0% to 1.5% in anti-CTLA-4 antibodies. However, only a handful of cases of such devastating complications have been reported in anti-PD-1 antibodies such as pembrolizumab and nivolumab. We here report a case of intestinal perforation in a patient treated with nivolumab.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados